"Servier will pay $1.8 billion in cash upfront and $200 million in potential future milestone payments for vorasidenib as well as a small percentage of royalties for U.S. net sales of acute myeloid leukemia treatment Tibsovo and U.S. net sales of vorasidenib, if the experimental therapy is approved by the Food and Drug Administration. " source marketwatch
Its is worth noting that the company currently has a M/C of $2.3 billion .
Todays action very much depends on activity among day traders.
The stock also carries a 8% short interest whom may fell a squeeze.
I have included levels to watch and in particular the 200ma and gap fill resistance.